Thomas Civik
Président chez REPARE THERAPEUTICS INC.
Fortune : 855 954 $ au 31/05/2024
Profil
Thomas Civik is currently the Independent Chairman at Imcheck Therapeutics SAS, Repare Therapeutics, Inc., and Pyxis Oncology, Inc. He previously served as the President, Chief Executive Officer & Director at Five Prime Therapeutics, Inc. from 2020 to 2021.
Prior to that, he was the Vice President-Avastin Sales & Marketing at Genentech, Inc. and the Chief Commercial Officer at Foundation Medicine, Inc. from 2017 to 2019.
Civik holds an undergraduate degree from St. Norbert College, Inc. and an MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC.
0,38% | 18/04/2024 | 221 886 ( 0,38% ) | 829 854 $ | 31/05/2024 |
REPARE THERAPEUTICS INC.
0,02% | 15/04/2024 | 7 500 ( 0,02% ) | 26 100 $ | 31/05/2024 |
Postes actifs de Thomas Civik
| Sociétés | Poste | Début |
|---|---|---|
| REPARE THERAPEUTICS INC. | Président | 07/09/2021 |
| PYXIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/09/2021 |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Président | 23/03/2023 |
Anciens postes connus de Thomas Civik
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Directeur Général | 16/04/2021 |
| FOUNDATION MEDICINE INC | Corporate Officer/Principal | 01/09/2019 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Sales & Marketing | - |
Formation de Thomas Civik
| Kellogg School of Management | Masters Business Admin |
| St. Norbert College, Inc. | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REPARE THERAPEUTICS INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Foundation Medicine, Inc.
 Foundation Medicine, Inc. Medical/Nursing ServicesHealth Services Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded on January 10, 2010 and is headquartered in Cambridge, MA. | Health Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Health Technology |
